Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) have received a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $54.71.

Several research firms have commented on RETA. Zacks Investment Research downgraded Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Cowen restated a “buy” rating on shares of Reata Pharmaceuticals in a report on Tuesday, November 14th. ValuEngine downgraded Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Robert W. Baird restated a “buy” rating and set a $47.00 price objective on shares of Reata Pharmaceuticals in a report on Tuesday, October 24th. Finally, Jefferies Group reiterated a “buy” rating and issued a $44.00 price target on shares of Reata Pharmaceuticals in a report on Friday, October 6th.

Reata Pharmaceuticals (NASDAQ:RETA) opened at $25.33 on Monday. Reata Pharmaceuticals has a fifty-two week low of $18.51 and a fifty-two week high of $40.88. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of -0.15.

Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.11). The business had revenue of $12.60 million during the quarter, compared to the consensus estimate of $12.54 million. The company’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts predict that Reata Pharmaceuticals will post -1.9 earnings per share for the current year.

In related news, Director James Edward Bass purchased 3,888 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were acquired at an average cost of $24.02 per share, for a total transaction of $93,389.76. Following the acquisition, the director now owns 52,089 shares of the company’s stock, valued at approximately $1,251,177.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 44.00% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Crestline Management LP acquired a new stake in shares of Reata Pharmaceuticals in the 3rd quarter worth $1,880,000. First Allied Advisory Services Inc. acquired a new stake in shares of Reata Pharmaceuticals in the 3rd quarter worth $203,000. Alyeska Investment Group L.P. acquired a new stake in shares of Reata Pharmaceuticals in the 3rd quarter worth $2,832,000. California State Teachers Retirement System boosted its position in shares of Reata Pharmaceuticals by 21.2% in the 3rd quarter. California State Teachers Retirement System now owns 18,325 shares of the company’s stock worth $570,000 after purchasing an additional 3,200 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Reata Pharmaceuticals by 83.2% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 49,828 shares of the company’s stock worth $1,550,000 after purchasing an additional 22,628 shares in the last quarter. 29.61% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Reata Pharmaceuticals, Inc. (RETA) Receives Average Recommendation of “Buy” from Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/04/reata-pharmaceuticals-inc-reta-receives-average-recommendation-of-buy-from-brokerages.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Analyst Recommendations for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.